but gonadotrophin concentrations, follicular development and ovulation are suppressed (Liu et al., 1987; Shoupe et al., 5 To whom correspondence should be addressed 1987b; . Immediately after ovulation, the The effects of low daily doses of the antiprogestin mifeprisformation of corpus luteum is not affected, but the development tone (RU 486) on ovarian and endometrial function were of secretory endometrium is retarded . studied. The study included one control cycle, three treatLater, during the luteal phase, bleeding occurs due to an ment cycles and one follow-up cycle. During the treatment effect on the endometrium, while luteal regression occurs cycles, either 0.1 (n ⍧ 5) or 0.5 (n ⍧ 5) mg of mifepristone inconsistently (Schaison et al., 1985; Shoupe et al., 1987a ; was administered once daily. Urine samples were collected Garzo et al., 1988; . During pregnancy, three times weekly during the control and treatment cycles mifepristone acts on the decidua (Schindler et al., 1985) and also induces myometrial activity, as well as increasing and pregnanediol glucuronide and oestrone glucuronide myometrial sensitivity to prostaglandins (Swahn and Bygdeand luteinizing hormone (LH) were quantified by radioman, 1988).
immunoassay. Blood samples for cortisol measurement
The various effects of antiprogestins on the hypothalamicwere collected once weekly and for serum glycodelin at the pituitary system and the endometrium may be useful for onset of menstruation. An endometrial biopsy was obtained contraceptive purposes by inhibiting ovulation, preventing or in the mid-luteal phase in the control cycle and in the first disrupting implantation or by inducing luteal regression and and third treatment cycles and analysed by morphometric menstrual bleeding. To date, mifepristone has been used as an and histochemical methods. Binding of Dolichus biflorus effective postcoital method of contraception (Glasier et al. , agglutinin (DBA) lectin was measured and expression of 1992; Webb et al., 1992) and in the early luteal phase as a progesterone and oestrogen receptors and glycodelin were once-a-month pill (Gemzell Danielsson et al., 1993) . If the analysed immunohistochemically. All cycles studied were endometrium is more sensitive to the antiprogestagenic effect ovulatory with an LH peak and elevated pregnanediol of mifepristone compared to the ovary or the hypothalamicglucuronide concentrations. Follicular development seemed pituitary system, it is possible that a low-dose regimen could normal as judged by ultrasound examination. The length be developed that would inhibit endometrial maturation and of the menstrual cycle and the menstrual bleeding were prevent implantation, without disturbing ovulation and the not significantly altered. Following administration of 0.5 normal rhythm of the menstrual cycle. Intermittent or daily mg mifepristone/day, endometrial development appeared treatment would be more practical than once-a-month treatto be slightly retarded and glandular diameter was significment, and would preclude failure due to possible individual antly reduced. Furthermore, significant decreases in DBA variations in the receptive phase.
lectin binding and endometrial expression of glycodelin
The aim of the present study was to evaluate this possibility. were observed. Daily doses of 0.1 mg did not have any A low dose of mifepristone, 0.1 or 0.5 mg, was administered significant effect on the endometrium. No differences in daily and the effect on ovarian function and endometrial oestrogen or progesterone receptor immunoactivity development and function was studied. between control and treatment cycles were seen. This study provides further evidence that endometrial function is Materials and methods sensitive even to doses of antiprogestin that are low enough not to disturb ovulation. It remains to be established None of the women had used steroidal contraceptives or an who was unaware of the precise cycle day and whether the biopsy had been taken in a control or a treatment cycle. intrauterine device for a minimum of 3 months prior to the study. Gynaecological examination was performed on admission. The subjects, who were not sterilized, were advised to use barrier methods Immuno-and lectin histochemistry for contraception during the study and all subjects were asked to A second portion of each biopsy was immediately frozen in liquid keep daily records on any side-effects and bleeding. Serum chemistry nitrogen and kept at -70°C. It was then mounted in an embedding analyses were done at admission and at the end of treatment. medium which, in addition to non-reactive ingredients, contained The study included one control cycle, three treatment cycles and 10.24% polyvinyl alcohol and 4.26% polyethylene glycol (O.C.T. a follow-up cycle. During the treatment cycles, mifepristone (RU Compound; Miles Inc., Elkhart, IN, USA) at -17°C and sectioned to 8-486; Roussel Uclaf, Paris, France) was administered as daily oral 10 mm using a Reichert-Jung Cryocut 1800 (Cambridge Instruments doses of either 0.1 mg (n ϭ 5) or 0.5 mg (n ϭ 5) at 21.00 h. The GmbH, Nussloch, Germany). The sections were placed on glass slides follicular phase was defined as the period between the first day of and air dried for 15-20 min before a 10 min fixation in acetone. menstrual bleeding (cycle day 1) and the day of urinary luteinizing Thereafter, the mounted sections were wrapped in Parafilm and stored hormone (LH) peak, both days inclusive. The luteal phase was defined at -70°C until processed for immuno-or lectin histochemistry. as the period between cycle day LHϩ1 and the day prior to the next Progesterone receptors (PR) were detected using the Abbot PgRmenstrual period, both days included. Follicular growth was monitored ICA monoclonal assay system (Abbot Laboratories Inc., North once weekly by pelvic ultrasonography.
Chicago, IL, USA). Localization of oestrogen receptors (ER) was performed with monoclonal antibody ER1D5 (Immunotech. SA,
Hormone determinations
Marseilles, France) and the Vectastain Elite ABC immunoperoxidase detection system (Vector Laboratories Inc., Burlingham, CA, USA) Morning urine was collected three times weekly during control according to the instructions of the manufacturer. and treatment cycles. The samples were analysed for pregnanediol
The secretory components of the endometrium were detected by glucuronide, oestrone glucuronide and LH using radioimmunoassay lectin histochemistry using biotinylated Dolichus biflorus agglutinin (Cekan et al., 1986) . Hormone concentrations in the urine were (DBA) lectin at a concentration of 5 µg/ml and the Vectastain Elite expressed per gram of creatinine (Metcalf and Hunt, 1976) . For ABC immunoperoxidase detection system (Vector Laboratories Inc.). creatinine analysis, a commercial kit (Sigma Diagnostics, St Louis, DBA binds to N-acetylgalactosamine and galactose residues present MO, USA, procedure no. 555) was used. In addition, all subjects in the glandular secretion of the mid-luteal phase endometrium (Mazur determined the LH peak in urine samples collected twice daily from et al., 1989) . As a negative control, DBA was co-incubated with the approximately cycle day 10 to day LHϩ2 by using a rapid self-test corresponding carbohydrate ligand at 200 mM concentration, which (Clearplan; Searle Unipath Ltd., Bedford, UK).
completely inhibited the binding. The individual steroid concentrations were normalized around the For the staining of glycodelin, tissue sections were treated with day of the LH peak, and the area under the curve was calculated by phosphate-buffered saline (PBS) containing Tween 20 (0.005%) for the trapezoidal method for each subject and cycle for the following 10 min at room temperature and then incubated with normal porcine periods: pregnanediol glucuronide from LHϩ1 to LHϩ11, and serum 1:10 in PBS for 20 min. Immunoaffinity purified polyclonal oestrone glucuronide and LH from LH-5 to LHϩ5.
antibody against human glycodelin (Kämäräinen et al., 1996) was Once weekly during treatment, at about 9.00 h, a blood sample applied (5 µg/ml) for 1 h at room temperature. After incubation, the was obtained for measurement of cortisol (Sufi et al., 1986) . Serum slides were washed three times in PBS for 2 min. Specific binding concentrations of glycodelin (Dell et al., 1995) were measured once of the primary antibody was detected using a complex of biotinylated monthly at onset of menstruation by immunofluorometric assay porcine anti-rabbit immunoglobulins (Dako, E 353) diluted 1:300, (Kämäräinen et al., 1994) .
for 40 min. The slides were washed three times with PBS for 2 min each, incubated with 0.6% hydrogen peroxide in methanol for 5 min Endometrial biopsy to block endogenous peroxidase activity, and then washed again three Using a Randall curette, an endometrial biopsy was obtained from times for 2 min each in PBS prior to incubation for 30 min with the fundus and upper part of the uterus. A biopsy was taken in avidin-biotin complex/horseradish peroxidase (Dako Laboratories, control, first and third treatment cycles on one of the cycle days Copenhagen, Denmark, code no. K 355) prepared according to the LHϩ5 to LHϩ8 according to the LH self-test. No cervical dilatation instructions. After three periods of 2 min each in PBS, the peroxidase or local anaesthesia was used. The endometrial material was assessed substrate solution 3-amino-9-ethylcarbazole (ACE; Sigma Products, by morphometric and histochemical analyses.
St Louis, MO, USA) was added. When incubated for 5 min the sections were rinsed with tap water, counterstained with 25% Meyers Morphometric analyses haematoxylin (Kebo, Stockholm, Sweden) for 90 s, and mounted One part of the biopsy material was immediately fixed in Bouin's with coverslips. Sections of human first trimester decidua were used solution and used for light microscopic examination (ϫ400) after as a positive control. As a negative control, the rabbit antiglycodelin embedding in paraffin wax and staining with haematoxylin. Morphoantiserum was replaced with the immunoglobulin (Ig) G fraction of metric analyses were performed, measuring the number of glands per normal rabbit serum or with PBS. mm 2 , the number of glandular and stromal mitoses per 1000 glandular Immuno-and lectin histochemical stainings were evaluated blindly or stromal cells respectively, glandular diameter (mm), glandular by two independent persons, using a Zeiss light microscope at ϫ200 epithelial height (mm), the number of cells with basal vacuolization magnification. Observations were made in various, non-overlapping per 1000 glandular cells, the number of pseudostratified cells, as well fields of the whole section in two or three labelling experiments and as the degree of stromal oedema, predecidualization and leukocyte included stromal, luminal and glandular cells. The cells were assigned infiltration. The findings were used to determine the degree of a score of 0 to 4 based on the number of cells specifically stained as development of the endometrium and described as the day of the follows: 0 (0% positive cells); 1, very weak (Ͻ5% positive cells); 2, cycle according to Johannisson et al. (1987) . Microscopic evaluation weak (5-25% positive cells); 3, moderate (25-75% positive cells); or 4, strong (Ͼ75% positive cells). A similar scoring system has of the samples was performed at the end of the study by one person been used by Press et al. (1988) . The occurrence of specific staining for glycodelin was scored as absent (-), weak (ϩ), moderate (ϩϩ) or intense (ϩϩϩ).
Statistics
A log-normal distribution was assumed for the steroid hormones and LH concentrations (Gaddum, 1945) . The paired t-test was used for evaluating differences in urinary hormone concentrations between the control and treatment cycles. Differences in morphometric parameters, receptor concentrations, DBA-lectin binding, glycodelin concentrations and the length of the menstrual cycles and bleeding were evaluated by using the two-tailed Wilcoxon's signed ranks test. A P value Ͻ0.05 was considered statistically significant. The hormonal values are presented as geometric means with 95% confidence limits. LH peak and elevated progesterone concentrations and with follicular development judged by ultrasound. The length of the control cycle was 23-28 days. No statistical difference 55.5 Ϯ 12.0 to 39.7 Ϯ 9.7 µm after the third treatment could be found in cycle length between control, treatment and month, corresponding to a slight retardation of endometrial follow-up cycles. However, one woman, while suffering from development. influenza, experienced a prolonged follicular phase (27 days)
Immuno-and lectin histochemistry during the second month of daily treatment with 0.5 mg mifepristone, while the length of her luteal phase was ER and PR were specifically localized in cell nuclei. In the unchanged (11 days). This woman completed only two treatcontrols, steroid receptor staining was more marked in stromal ment cycles and hence her second biopsy was taken during than in glandular cells. During mifepristone treatment with the the second treatment month. The duration of menstrual bleeding higher dose (0.5 mg/day), the number of PR tended to increase (4-7 days) and subjectively evaluated blood loss were unafin epithelial and stromal cells, but no statistically significant fected by treatment. No irregular bleeding or spotting were changes were found. The ER concentration was not affected noted, and the results of serum chemistry analyses were within by the treatment. In control biopsies, normal secretory function the normal range and did not differ from control values. Two was indicated by a high degree of DBA-lectin binding. This patients taking the higher dose complained of acne during the binding was not significantly reduced after daily treatment first treatment month. In these subjects there were no problems with 0.1 mg mifepristone, while there was a significantly during the following treatment cycles. No other side-effects decreased (P Ͻ 0.01) binding during the third month of were observed. mifepristone treatment with 0.5 mg/day (Table II) .
Hormone concentrations Glycodelin in serum An LH peak was detected by the self-test in all control and
Serum concentration of glycodelin was measured at the time treatment cycles. This was also confirmed by the laboratory of menstruation (cycle day 1 Ϯ 2 days) and was in the range analyses. There was no statistical difference in the height of of values previously reported, 22.4-74.5 µg/l (mean 45.0), the LH peak (Figure 1 ). Urinary concentrations of oestrone (Seppälä et al., 1987; Swahn et al., 1993;  Gemzell Danielsson glucuronide and pregnanediol glucuronide were not significet al., 1996) . Serum glycodelin concentrations were not affected antly affected by the treatment. Plasma cortisol concentrations by 0.1 mg mifepristone daily. In the higher dose group, serum were within the normal range and did not differ between the glycodelin concentrations decreased slightly in four of the control and treatment cycles.
women (range 5.2-70.7 µg/l, mean 23.3) but increased (~2-fold) in one woman. In the latter subject, endometrial expresEndometrial morphometric analyses sion of glycodelin was abolished during treatment with 0.5 mg mifepristone/day. In the control cycles, there was an excellent relationship between the calculated cycle day based on the LH peak and Endometrial expression of glycodelin the histological dating of endometrial biopsies by morphometric analyses (Table I) . Following treatment with 0.1 mg/day, In control biopsies obtained on one of the cycle days LHϩ5-8 (mean 7.2), all but one specimen showed positive staining the endometrium did not differ from the normal secretory appearance of the controls. In the higher dose group, all the for glycodelin localized within the glandular lumen. During the first treatment month with 0.1 mg mifepristone daily, parameters included in the morphometric analysis, except for glandular diameter, were unchanged. The diameter of the no changes could be found, while the serum glycodelin concentration seemed to have decreased in the third treatment glands was significantly reduced (P Ͻ 0.05) from a mean of glandin is a well accepted and effective non-surgical method (mg) for termination of early pregnancy (see Bygdeman, 1995) . epristone in doses as low as 2 mg/day (Ledger et al., 1992;  b P Ͻ 0.01 (control compared to treatment months). Croxatto et al., 1993) or 10 mg once a week (Spitz et al., 1993) . It has previously been shown that treatment with a high dose of mifepristone (200 g) on day LHϩ2 will result in lack Mäentausta et al., 1993) , Control 1st month 3rd b month decreased concentrations of prostaglandin F 2α in uterine fluid (Gemzell Danielsson and Hamberg, 1994) (Batista et al., 1992; Croxatto et al., 1993) . These effects of various doses of mifepristone on its main target organs make a Cells were assigned a score as follows: -ϭ absent, ϩ ϭ weak, ϩϩ ϭ it potentially useful for contraceptive purposes, either by its moderate, ϩϩϩ ϭ intense. b One patient receiving 0.5 mg mifepristone had the second biopsy taken effects on folliculogenesis and ovulation (Baird et al., 1995;  during the second month (see text). Croxatto et al., 1995; Kekkonen et al., 1995) or by a direct effect on endometrium, decidua or corpus luteum to prevent cycles. The effect was more pronounced after treatment with implantation or interrupt early pregnancy. To date, mifepristone the higher dose of 0.5 mg per day (P Ͻ 0.05; Table III and has only been shown to be effective for contraception when Figure 2 ). The single negative control sample was collected used as an emergency postcoital method (Glasier et al., 1992 ; on day LHϩ6. This subject had a weak (ϩ) positive staining Webb et al., 1992) or on a regular basis in the early luteal for glycodelin in her first treatment cycle (0.5 mg/day) when phase as a once-a-month pill (Gemzell Danielsson et al., 1993) . the biopsy was obtained on cycle day LHϩ7. In the last
There are now results indicating a dissociation between the treatment cycle, the endometrial tissue was collected on LHϩ6 central effects of mifepristone on gonadotrophin-dependent folliculogenesis-ovulation and the direct effect on the endometand no staining was seen. rium Gemzell Danielsson et al., 1996) . 0.1 or 0.5 mg mifepristone was given for three consecutive cycles without disturbing ovulation or the normal menstrual This opens the possibility for the development of a lowdose regimen that would inhibit endometrial function without cycle rhythm. Urinary concentrations of pregnanediol glucuronide and oestrone glucuronide after treatment remained blocking ovulation. In the present study, a daily dose of either unchanged. Treatment with the higher dose caused a slight but be delayed for 6-13 days. The length of the luteal phase was unaffected. A dose of 5 mg of mifepristone once a obvious retardation of endometrial maturation at the expected time of implantation. This was reflected by decreased glandular week was sufficient to disturb endometrial development and secretory activity significantly and to inhibit the downdiameter. In agreement with the histological changes, there was a reduced DBA binding to the endometrial glands, regulation of PR normally occurring during the luteal phase. Endometrial morphology, PR concentration and serum indicating a reduced secretory activity. Even a minor change in secretory activity may result in lack of implantation, since concentrations of glycodelin were affected to a lesser extent with the lower dose. That the effect of low-dose treatment successful implantation depends on synchronization between the embryo and the development of a receptive endometrium with mifepristone on the endometrial function observed in this and the previously mentioned study could prevent (Davies et al., 1990) . The importance of precisely timed functioning of the endometrium is further supported by the implantation is supported by the results of Katkam et al. (1995) , who studied the effect of the antiprogestin onapristone studies of Lessey et al. (1995) , who investigated the expression of integrins as markers of endometrial maturation and uterine (ZK 98, 299) , given in low intermittent doses to bonnet monkeys. Four animals treated with 2.5 mg onapristone for receptivity.
Glycodelin (Dell et al., 1995) , also known as placental 17 cycles and another four treated with a 5 mg dose for 21 cycles did not conceive, while one animal treated with protein 14, is a glycoprotein with immunosuppressive and contraceptive activities (Julkunen et al., 1988; Okamoto et al., 5 mg became pregnant in the first treatment cycle. In the majority of cycles, ovulation was not disturbed but anovul-1991; Oehninger et al., 1995) . In the endometrium, glycodelin is secreted into the glandular lumen and uterine fluid around ation and luteal insufficiency occurred in some animals during prolonged treatment. Endometrial biopsies from 8 the peri-implantation period. Glycodelin concentrations in serum start to rise in the mid-luteal phase, reaching a maximum days after the midcycle oestradiol peak showed retardation with decreased glandular diameter. at the onset of the next menstrual period. If the luteal phase is inadequate, the circulating concentrations are lower (Joshi It is unlikely that the skin problem noted by two women treated with 0.5 g/day could be a direct result of the et al., 1986) . Reduction in serum glycodelin following treatment with mifepristone has previously been reported (Gemzell treatment because no problems with acne were noted for daily treatment with 200 mg mifepristone in 10 patients Danielsson et al., 1996) , and following treatment with mifepristone in combination with tamoxifen (Swahn et al., 1993) .
with meningeomas (Lamberts et al., 1991) . Furthermore, mifepristone has very low affinity for the androgen receptor However, measurements of circulating concentrations of glycodelin do not seem to predict a receptive endometrium (Wood and it does not bind to transcortin or sex hormone-binding globulin (Moguilewsky and Philibert, 1985) . The doses of et al ., 1990) , and recent evidence also indicates that glycodelin is not endometrium-specific. It is synthesized in haematopoetic mifepristone required to produce antiglucocorticoid effects are higher than those needed for anti-progestagenic activity tissues of the bone marrow (Kämäräinen et al., 1994) and perhaps other tissues. A more valuable method of assessing (Shoupe et al., 1987a) . Treatment with 2-10 mg mifepristone for 30 days had no effect on the peripheral concentration endometrial function might be to analyse glycodelin expression in an endometrial biopsy or in uterine fluid (Rizk et al., of cortisol or adrenocorticotrophic hormone (Ledger et al., 1992; Croxatto et al., 1993) , and serum cortisol was not 1992; Mackenna et al., 1993) . Measurement of glycodelin in endometrial tissue or uterine fluid may better reflect endometaffected by mifepristone treatment in the present study. It is believed that progestins suppress oestrogen action in rial function than the concentration in plasma, since influence by extrauterine sources of the protein is avoided.
the endometrium by down-regulating ER. Daily treatment with 50 mg mifepristone for 6 months resulted in increased In the present study, serum glycodelin decreased during treatment with 0.5 mg mifepristone per day, except for one ER concentrations in the stroma and cystic changes consistent with oestrogenic effects (Murphy et al., 1995) . The subject, in whom serum concentrations increased. In this subject, endometrial glycodelin was abolished by mifepristone significance of this 'unopposed oestrogen' effect during treatment with antiprogestin needs to be investigated further. treatment. The increased serum concentrations may thus have been due to the increased extrauterine release of glycodelin.
However, both onapristone and mifepristone have the ability to antagonize the action of oestrogen on the endometrium The endometrial expression of glycodelin was significantly decreased following daily administration of 0.5 g mifepristone.
in primates (Van Uem et al., 1989) . The immunoreactivity of ER and PR was unchanged after mifepristone treatment An explanation for the single glycodelin-negative control biopsy is probably that this biopsy was obtained too early in the present study, and no signs of endometrial stimulation were found. (cycle day LHϩ6). The same woman had a weak positive biopsy during the first treatment month when the biopsy was
The present study clearly shows that endometrial secretory activity is sensitive even to such low doses of an antiprogestin collected on day LHϩ7. The results of this study lend further support to the view that progesterone plays a role in endometrial that do not disturb ovarian function and ovulation. Furthermore, the concentrations of ER and PR were unaffected by glycodelin synthesis.
In a previous study, mifepristone was given as an the treatment and no signs of endometrial stimulation were recorded. It remains to be shown that the effects observed intermittent low dose of 2.5 or 5 mg once a week for 2 months, starting on cycle day 2 (Gemzell Danielsson et al., here on endometrial secretory activity also inhibit endometrial receptivity and implantation. 1996). Ovulation was not inhibited but could occasionally
